Innovating Works

Amgen

Desconocido
MOBILISE-D: Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement AMGEN LIMITED participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing...
2019-03-22 - 2024-06-30 | Financiado
GetReal Initiative: The GetReal Initiative AMGEN LIMITED participó en un H2020: H2020-JTI-IMI2-2017-11-single-stage The GetReal Initiative brings together partners from the IMI GetReal project to drive the adoption of tools, methodologies and best practice...
2018-06-26 - 2021-04-30 | Financiado
PARADIGM: Patients Active in Research and Dialogues for an Improved Generation of Medicines Advancing meaning... AMGEN LIMITED participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engage...
2018-06-04 - 2020-11-30 | Financiado
PREFER: Patient Preferences in benefit risk assessments during the drug life cycle Sofia ref. 115966 AMGEN LIMITED participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i....
2016-10-21 - 2022-05-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.